On February 27, 2026, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced that his department would move to reclassify approximately 14 peptides from the FDA's Category 2 restricted list to Category 1 -- a change that, if formalized, would restore the ability of licensed compounding pharmacies to prepare these compounds with a valid prescription.[1]
The announcement generated immediate attention across clinics, telehealth platforms, and online peptide communities. But the space between a political signal and a formal regulatory action is significant, and understanding that gap matters if you're considering peptides or currently using them.
- What was announced: HHS Secretary Kennedy stated that ~14 peptides would be moved from Category 2 (restricted) to Category 1 (compoundable with prescription).
- What hasn't happened yet: No formal FDA rulemaking or Federal Register notice has been published as of March 17, 2026.
- What it would mean: Licensed compounding pharmacies could legally prepare these peptides for patients with a valid physician prescription.
- What it would not mean: Reclassification is not FDA approval. These peptides would remain unapproved drugs with limited human clinical data.
Quick facts
- Date of announcement
- February 27, 2026
- Peptides affected
- ~14 of 19 Category 2 substances
- Current status
- Pending formal FDA action
- Key agencies
- HHS, FDA
- Formal rule published
- No (as of March 17, 2026)
What happened
On February 27, 2026, Secretary Kennedy released a public statement through HHS indicating that his department had directed the FDA to begin the process of reclassifying approximately 14 of the 19 bulk drug substances currently on the agency's Category 2 list.[1] The statement framed the move as restoring patient access to peptide therapies that, according to Kennedy, had been unnecessarily restricted.
The Category 2 list was established as part of the FDA's ongoing review of bulk drug substances used in compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.[3] Substances placed on Category 2 are those the FDA determined lack sufficient evidence of safety for compounding use. When a substance lands on Category 2, compounding pharmacies are effectively prohibited from using it.
Kennedy's statement did not specify a timeline for formal FDA action, nor did it name every peptide affected. However, based on the Category 2 list and reporting from multiple industry sources, the peptides expected to be reclassified include several of the most widely discussed compounds in the peptide therapy space.
Which peptides are affected
The FDA's Category 2 list contained 19 bulk drug substances as of early 2026.[2] According to the Kennedy announcement, approximately 14 of these would move to Category 1. Based on the current Category 2 list and available industry reporting, the peptides believed to be affected include:[2][4]
- BPC-157 -- Body Protection Compound, studied for tissue repair and gut health
- TB-500 (Thymosin Beta-4) -- studied for wound healing and inflammation
- Sermorelin -- a growth hormone-releasing hormone analog
- AOD-9604 -- a modified fragment of growth hormone studied for fat metabolism
- CJC-1295 -- a growth hormone-releasing hormone analog with extended half-life
- Ipamorelin -- a growth hormone secretagogue
- Thymosin Alpha-1 -- an immune-modulating peptide
- DSIP (Delta Sleep-Inducing Peptide) -- studied for sleep regulation
- Epithalon -- studied for telomerase activation
- Selank -- a synthetic peptide studied for anxiolytic effects
- Semax -- a neuropeptide studied for cognitive function
- GHK-Cu -- a copper-binding peptide used in wound healing and skin care
- MOTS-c -- a mitochondrial-derived peptide studied for metabolic regulation
- KPV -- a tripeptide studied for anti-inflammatory effects
The remaining ~5 substances on the Category 2 list are reportedly under continued review and may remain restricted pending additional safety evaluation.
What Category 1 vs Category 2 means
The FDA's category system for bulk drug substances determines whether compounding pharmacies can legally use a substance to prepare medications.[2]
Category 1 means a substance has been evaluated and can be used by compounding pharmacies operating under Section 503A (with a patient-specific prescription from a licensed prescriber) or Section 503B (outsourcing facilities that can compound without individual prescriptions).[3] In practical terms, Category 1 means: your doctor can write a prescription, and a licensed compounding pharmacy can fill it.
Category 2 means the FDA determined there is insufficient evidence that the substance is safe for compounding use. While a substance is on Category 2, compounding pharmacies are not permitted to use it. This is the status that most of the peptides listed above have carried since 2023.[2]
To be clear about what Category 1 is not: it is not FDA approval. An FDA-approved drug (like semaglutide or insulin) has gone through the full New Drug Application process -- Phase I, II, and III clinical trials, manufacturing review, and post-market surveillance. Category 1 simply means a substance can be compounded. The peptides in question would still lack the extensive human trial data that FDA-approved drugs carry.[5]
The gap between signal and action
This is the part that matters most right now. Kennedy's February 27 statement is a political signal from the head of HHS. It is not, as of March 17, 2026, a formal regulatory action.[4]
For the reclassification to take legal effect, the FDA would typically need to:
- Conduct an internal review of the safety and suitability evidence for each substance
- Publish a proposed rule or notice in the Federal Register
- Accept public comment (typically a 30- to 60-day window)
- Issue a final rule reflecting any changes based on comments received
- Update the official Category lists on FDA.gov
This process can take months. In some cases, the FDA could move more quickly through an interim enforcement discretion approach -- essentially signaling to compounding pharmacies that it will not enforce Category 2 restrictions while the formal process proceeds. But as of this writing, no such interim guidance has been published.
There is also the question of institutional dynamics. The FDA has historically operated with significant independence from HHS political leadership. Whether the career staff at the FDA's Office of Pharmaceutical Quality will move at the pace Kennedy's statement implied remains to be seen.[5]
What this means for you
If you're someone who has used peptides, is considering peptides, or is watching this space closely, here's a practical framework for thinking about the Kennedy announcement:
If you currently have a prescriber and compounding pharmacy relationship: Ask your prescriber whether they are tracking the reclassification and whether their pharmacy plans to begin compounding affected peptides once formal action occurs. Some pharmacies may begin preparing ahead of the formal rule change; others will wait for explicit FDA guidance.
If you've been sourcing peptides from gray-market vendors: The reclassification, if finalized, would create a legitimate pathway for many of the peptides that were previously only available outside the regulated system. This is an opportunity to transition to a safer supply chain -- compounding pharmacies that operate under FDA oversight, with quality controls, sterility testing, and proper labeling.
If you're new to peptides: Wait for the regulatory dust to settle. The reclassification creates a clearer path, but it hasn't been formalized yet. Use this time to research, find a knowledgeable prescriber, and understand the evidence base for the specific peptide you're interested in. Many of these compounds have limited human clinical data, and working with a qualified healthcare provider is important regardless of legal status.[7]
What not to do: Don't rush to gray-market sources because of the announcement. The enforcement actions against vendors like Peptide Sciences, Amino Asylum, and Paradigm Peptides are continuing regardless of the reclassification signal. Gray-market peptides carry documented quality risks — including contamination, incorrect potency, and wrong-molecule substitutions, according to independent testing data.[8]
The Kennedy reclassification is a meaningful development. If it proceeds through formal channels, it will represent the most significant expansion of legal peptide access in the United States in years. But it hasn't happened yet, and the responsible move is to stay informed, work with licensed professionals, and make decisions based on what has actually changed -- not what has been announced.
References
- [1]U.S. Department of Health and Human Services. “Statement by Secretary Kennedy on Compounding and Patient Access to Peptide Therapies.” HHS.gov Press Release. 2026. LinkGovernment statement
- [2]U.S. Food and Drug Administration. “Bulk Drug Substances That Can Be Used in Compounding Under Section 503A and 503B: Category 2 List.” FDA.gov. 2023. LinkRegulatory document
- [3]U.S. Food and Drug Administration. “Compounding Laws and Policies: Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.” FDA.gov. 2024. LinkRegulatory guidance
- [4]Alliance for Natural Health USA. “Peptide Access and the FDA Category System: A Policy Analysis.” ANH-USA Policy Brief. 2025. LinkPolicy analysis
- [5]McGuire MF, Brewer JR. “Regulatory Landscape for Compounded Peptide Therapies in the United States: A Review.” Therapeutic Innovation & Regulatory Science. 2025. 59:112-124 DOIReview article
Peer-reviewed overview of FDA peptide compounding regulations and enforcement trends.
- [7]Janoshik Analytical. “Public peptide testing database — 2024 aggregate results.” 2024. Link
Independent analytical testing laboratory (Prague). 43% of gray-market peptides failed purity claims; 23% of retatrutide samples contained the wrong molecule.
- [8]Vasireddi A, Srinivas S, Gurtner GC. “BPC 157: A Comprehensive Review of Its Regenerative Effects and Therapeutic Potential.” Tissue Engineering Part B: Reviews. 2025. DOISystematic review
Most recent comprehensive review confirming evidence is overwhelmingly preclinical.
The regulatory landscape is moving fast
Get notified when new regulatory changes affect peptide access. We track the FDA, so you don't have to.
Related content
BPC-157
Research profile for one of the peptides potentially affected by reclassification.
NewsWhat Happened to Peptide Sciences
How gray-market enforcement connects to the reclassification push.
NewsFDA Peptide Categories Explained
A deeper look at the Category 1, 2, and 3 classification system.
PeptideTB-500
Another Category 2 peptide affected by potential reclassification. Research profile and evidence.
PeptideThymosin Alpha-1
Approved in 35+ countries but not in the US — a key peptide in the reclassification discussion.
GuideWhat Are Peptides?
A foundational primer for understanding the compounds at the center of the reclassification debate.
Disclaimer
Peptide Garden is an educational resource, not a medical provider. This article reflects information available as of March 17, 2026. The regulatory status of the peptides discussed is evolving and may change after publication. Nothing in this article constitutes medical advice, legal advice, or a recommendation to use any peptide therapy. Always consult a licensed healthcare provider before making decisions about peptide use, and verify current regulatory status through official FDA channels.